Focused On-demand Library for Calmodulin-like protein 5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9NZT1

UPID:

CALL5_HUMAN

Alternative names:

Calmodulin-like skin protein

Alternative UPACC:

Q9NZT1; Q5SQI3; Q8IXU8

Background:

Calmodulin-like protein 5, also known as Calmodulin-like skin protein, plays a crucial role in the human body by binding calcium. This process is essential for the terminal differentiation of keratinocytes, which are pivotal in the formation of the epidermis, the outermost layer of the skin. The protein's ability to interact with calcium ions highlights its significance in cellular processes.

Therapeutic significance:

Understanding the role of Calmodulin-like protein 5 could open doors to potential therapeutic strategies. Its involvement in skin cell differentiation makes it a promising target for research in skin-related disorders and regenerative medicine. The exploration of this protein's functions could lead to breakthroughs in treating skin conditions and enhancing wound healing.